Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several high-level statements about class, acid reduction, indications (ulcers/GERD/hypersecretory conditions), and common adverse reactions match the provided label excerpts. However, multiple claims are not supported by the excerpts (OTC availability, injection availability, onset time/duration of effect, “serious side effects are rare,” irregular heartbeat, dry mouth, fatigue, specific ulcer-healing/prevention phrasing), and some claims overgeneralize beyond what is shown in the provided label text.
Category Scores
Accurate Statements
Famotidine belongs to the class of histamine H2-receptor antagonists.
Label 4 CONTRAINDICATIONS: contraindicated in hypersensitivity to famotidine or other histamine-2 (H2) receptor antagonists.
Famotidine reduces the amount of acid produced by the stomach.
Label 7.1: famotidine reduces absorption of other drugs due to its effect on reducing intragastric acidity.
Famotidine is prescribed to treat gastroesophageal reflux disease (GERD).
Label 1 INDICATIONS AND USAGE: treatment of symptomatic nonerosive GERD and erosive esophagitis due to GERD diagnosed by biopsy.
Famotidine is prescribed for conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome.
Label 1 INDICATIONS AND USAGE: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
Famotidine may cause headache.
Label 6.1: adverse reactions ≥1% include headache.
Famotidine may cause dizziness.
Label 6.1: adverse reactions ≥1% include dizziness.
Famotidine may cause constipation.
Label 6.1: adverse reactions ≥1% include constipation.
Unsupported Statements
Famotidine is used to treat and prevent ulcers in the stomach and intestines.
Label excerpt supports treatment of active duodenal and gastric ulcers and reduction of risk of duodenal ulcer recurrence, but does not support a generalized statement “prevent ulcers in the stomach and intestines.”
By decreasing stomach acid, famotidine helps to heal existing ulcers.
The label excerpt includes treatment indications for active duodenal/gastric ulcers and healing outcomes in clinical studies (e.g., healing DU), but it does not explicitly connect “decreasing stomach acid” to healing in the provided text.
By decreasing stomach acid, famotidine helps prevent new ulcers from forming.
Label excerpt supports reduction of risk of duodenal ulcer recurrence, but it does not explicitly state “prevents new ulcers from forming” nor link this to “decreasing stomach acid” in the provided text.
Famotidine alleviates symptoms associated with GERD, like heartburn.
Label excerpt indicates symptomatic nonerosive GERD, but does not specifically mention heartburn or symptom examples.
Famotidine is available in oral tablets.
The provided label is specifically PEPCID tablets (20 mg and 40 mg), but the claim is not directly stated as a product availability statement within the excerpts (it is implied by the drug being tablets).
Famotidine is available in oral suspension.
Label excerpts mention that some dosage adjustments may require switching to other formulations (e.g., oral suspension), but the claim “available in oral suspension” is broader than what is explicitly stated.
Famotidine is available as an injectable solution.
No label excerpt provided mentions an injectable solution.
Famotidine is available over-the-counter and by prescription.
No provided label excerpt addresses OTC vs prescription availability.
Oral formulations of famotidine typically begin to reduce stomach acid within an hour of administration.
No onset-time statement is included in the provided label excerpts.
The effects of oral famotidine can last for up to 12 hours.
No duration-of-effect statement (e.g., up to 12 hours) appears in the provided label excerpts.
Famotidine may cause diarrhea.
The provided label excerpt lists headache, dizziness, and constipation (≥1%); it does not state diarrhea as an adverse reaction.
Famotidine may cause fatigue.
The provided label excerpt does not list fatigue.
Famotidine may cause dry mouth.
The provided label excerpt does not list dry mouth.
Serious side effects of famotidine are rare.
No label excerpt provided states that serious side effects are rare.
Serious side effects of famotidine can include irregular heartbeat.
The provided warnings mention CNS adverse reactions and prolonged QT intervals, but the excerpt does not mention “irregular heartbeat.”
Serious side effects of famotidine can include signs of an allergic reaction.
The label excerpt supports hypersensitivity reactions such as anaphylaxis/angioedema/urticaria, but the specific phrasing “signs of an allergic reaction” is broader and not explicitly listed as “signs.”
Famotidine is an older medication.
No label excerpt provided addresses age of the medication.
Famotidine's original patents have long expired.
No label excerpt provided addresses patent status.
Generic versions of famotidine are widely available.
No label excerpt provided addresses generic availability.
Contradictions
Important Omissions
No dose/regimen details were provided in the response claims (e.g., specific tablet dosing for symptomatic nonerosive GERD, duodenal ulcer recurrence risk reduction, and limits/recommendations by renal function).
Importance:
Moderate
The response did not include key administration timing instructions from the label (e.g., once daily before bedtime; twice daily in the morning and before bedtime; may be taken with or without food; may be given with antacids).
Importance:
Moderate
The response did not mention the label warnings related to CNS adverse reactions in elderly and patients with moderate/severe renal impairment, including confusion/delirium/hallucinations and that dosage adjustments are recommended in renal impairment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overbroad safety claims (e.g., irregular heartbeat, rarity of serious side effects) and missing renal/CNS warning emphasis could mislead users, though several common adverse reactions (headache, dizziness, constipation) were supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts (especially OTC/injectable availability, onset/duration of acid suppression, “rare” serious side effects, and specific serious adverse effects like irregular heartbeat; also several additional adverse reactions not listed in the excerpt).
Suggested Improvement
Limit statements to label-supported items from the provided excerpts: indications (active DU/GU, symptomatic nonerosive GERD, biopsy-diagnosed erosive esophagitis, pathological hypersecretory conditions such as Zollinger-Ellison, reduction of duodenal ulcer recurrence), label-supported adverse reactions (headache, dizziness, constipation; hypersensitivity reactions such as anaphylaxis/angioedema/urticaria), and avoid making claims about OTC status, injectable formulation, onset/duration times, and unlisted adverse reactions.